Dynavax Technologies reported $35.74M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.13B 73M
Adma Biologics ADMA:US $ 15.89M 1.78M
Agenus AGEN:US $ 18.91M 39K
Amgen AMGN:US $ 1.33B 99M
AstraZeneca AZN:LN 268.26B 35.48B
Astrazeneca AZN:US 3.27B 209M
Biogen BIIB:US $ 572.6M 62.3M
Biomarin Pharmaceutical BMRN:US $ 196.83M 2.22M
Bristol Myers Squibb BMY:US $ 1.78B 46M
Chimerix CMRX:US 5.84M 208K
Dynavax Technologies DVAX:US $ 35.74M 4.27M
Gilead Sciences GILD:US $ 1.36B 274M
Glaxosmithkline GSK:US 1.96B 726M
Idera Pharmaceuticals IDRA:US $ 2.66M 261K
Merk MRK:US $ 2.42B 118M
Minerva Neurosciences NERV:US $ 2.83M 196.19K
Nektar Therapeutics NKTR:US $ 21.44M 5.9M
Neurocrine Biosciences NBIX:US $ 182.8M 17.9M
Novartis NOVN:VX 3.59B 91M
Pfizer PFE:US $ 3.2B 506M
Regeneron Pharmaceuticals REGN:US $ 476.3M 26.3M
Sarepta Therapeutics SRPT:US $ 154.32M 82.48M
Tg Therapeutics TGTX:US $ 12.64M 7.97M
Vertex Pharmaceuticals VRTX:US $ 215.3M 100K